Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 3
3(75.0%)
Phase 4
1(25.0%)
4Total
Phase 3(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07346859Phase 3Recruiting

Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)

Role: lead

NCT05422365Phase 3Completed

Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults

Role: lead

NCT05245734Phase 4Recruiting

Human Anti-D (rh) Immunoglobulin (Rhesoglobin) Efficacy, Safety and Some Pharmacokinetics Parameters in Pregnant Women

Role: lead

NCT04500067Phase 3Completed

Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment

Role: lead

All 4 trials loaded